Fierce Pharma13h
Novo's commercial strategy head hits the exit, prompting a slew of executive team shakeups
Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...
Eli Lilly and Novo Nordisk are tackling heart health next
After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart ...
Novo Holdings nearly doubles earnings as Wegovy swells coffers
LONDON/COPENHAGEN (Reuters) -Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled ...
Novo Nordisk's weight loss drug Wegovy is now cheaper for even more patients
Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half ...
BoFA Says Novo Nordisk May Miss Q1 Expectations as Wegovy, Ozempic Sales Lag
GDANSK/LONDON (Reuters) - Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales ...
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...
NBC New York7d
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product'
Copenhagen, DENMARK — Novo Nordisk defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss ...
U.S. News & World Report9d
Novo Nordisk to Pay $2 Billion for New Weight Loss Drug
Novo Nordisk to Pay $2 Billion for New Weight Loss Drug TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion ...
Novo Nordisk to Pay Up to $2 Billion for Rights to Experimental Obesity and Diabetes Drug
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...